OPKO Health Inc. (NASDAQ:OPK) has a beta of 1.77, a 12-month trailing P/E ratio of 19.10, and a growth ratio of 1.59. The stock’s Relative Strength Index (RSI) is 43.08, with weekly volatility at 4.82% and ATR at 0.17. The OPK stock’s 52-week price range has touched low of $2.18 and a $6.47 high. Its shares traded lower over the last trading session, losing -1.63% on 06/04/21. The shares fell to a low of $3.60 before closing at $3.61. Intraday shares traded counted 2.84 million, which was 43.84% higher than its 30-day average trading volume of 5.05M. OPK’s previous close was $3.67 while the outstanding shares total 640.85M.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Investors have identified the Diagnostics & Research company OPKO Health Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.46 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
OPKO Health Inc. (OPK) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For OPK, the company has in raw cash 89.5 million on their books with 17.82 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 599.05 million total, with 403.93 million as their total liabilities.
OPK were able to record 16.79 million as free cash flow during the 08/10/2021 quarter of the year, this saw their quarterly net cash flow reduce by 17.29 million. In cash movements, the company had a total of 26.04 million as operating cash flow.
Potential earnings growth for OPKO Health Inc. (OPK)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/10/2021 quarter of the year, OPKO Health Inc. recorded a total of 545.16 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 61.21% coming in sequential stages and their sales for the 08/10/2021 quarter increasing by 9.26%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 363.51 million trying to sell their products during the last quarter, with the result yielding a gross income of 181.66 million. This allows shareholders to hold on to 640.85M with the recently reported earning now reading 0.05 cents per share. This is a figure that compared to analyst’s prediction for their 08/10/2021 (0.05 cents a share).
Having a look at the company’s valuation, the company is expected to record 0.07 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on OPK sounds very interesting.
Is the stock of OPK attractive?
In related news, CEO & Chairman, FROST PHILLIP MD ET AL bought 400,000 shares of the company’s stock in a transaction that recorded on May 25. The purchase was performed at an average price of 3.64, for a total value of 1,455,972. As the purchase deal closes, the CEO & Chairman, FROST PHILLIP MD ET AL now bought 75,000 shares of the company’s stock, valued at 273,745. Also, SVP OPKO; Exec Chairman BRLI, Cohen Jon R bought 50,000 shares of the company’s stock in a deal that was recorded on May 10. The shares were cost at an average price of 3.81 per share, with a total market value of 190,500. Following this completion of disposal, the CEO & Chairman, FROST PHILLIP MD ET AL now holds 75,000 shares of the company’s stock, valued at 287,742. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.50%.
